688117 圣诺生物
已收盘 12-05 15:00:01
资讯
新帖
简况
圣诺生物(688117.SH):五肽-18通过化妆品新原料备案
智通财经 · 12-03 18:07
圣诺生物(688117.SH):五肽-18通过化妆品新原料备案
圣诺生物(688117)披露拟换届董事会人选,12月02日股价下跌0.99%
证券之星 · 12-02
圣诺生物(688117)披露拟换届董事会人选,12月02日股价下跌0.99%
圣诺生物最新公告:董事、高管拟合计减持不超0.024%股份
证券之星 · 11-30
圣诺生物最新公告:董事、高管拟合计减持不超0.024%股份
11月26日圣诺生物涨6.99%,华商智能生活灵活配置混合A基金重仓该股
证券之星 · 11-26
11月26日圣诺生物涨6.99%,华商智能生活灵活配置混合A基金重仓该股
每周股票复盘:圣诺生物(688117)维培那肽原料药获上市批准
证券之星 · 11-23
每周股票复盘:圣诺生物(688117)维培那肽原料药获上市批准
圣诺生物宣布其子公司获得中国医疗监管机构批准,维塞佩肽正式进入市场
美股速递 · 11-19
圣诺生物宣布其子公司获得中国医疗监管机构批准,维塞佩肽正式进入市场
圣诺生物(688117.SH):维培那肽原料药获得上市申请批准
智通财经 · 11-19
圣诺生物(688117.SH):维培那肽原料药获得上市申请批准
圣诺生物(688117)披露2025年中期权益分派实施公告,11月10日股价上涨0.26%
证券之星 · 11-10
圣诺生物(688117)披露2025年中期权益分派实施公告,11月10日股价上涨0.26%
每周股票复盘:圣诺生物(688117)前三季净利增123.03%
证券之星 · 11-02
每周股票复盘:圣诺生物(688117)前三季净利增123.03%
圣诺生物(688117)9月30日股东户数1.01万户,较上期减少9.53%
证券之星 · 10-28
圣诺生物(688117)9月30日股东户数1.01万户,较上期减少9.53%
图解圣诺生物三季报:第三季度单季净利润同比增长8.23%
证券之星 · 10-27
图解圣诺生物三季报:第三季度单季净利润同比增长8.23%
每周股票复盘:圣诺生物(688117)前三季度净利预增100.53%至145.10%
证券之星 · 10-19
每周股票复盘:圣诺生物(688117)前三季度净利预增100.53%至145.10%
股市必读:圣诺生物(688117)预计2025年1-9月扣非后净利润盈利1.13亿元至1.39亿元
证券之星 · 10-14
股市必读:圣诺生物(688117)预计2025年1-9月扣非后净利润盈利1.13亿元至1.39亿元
圣诺生物最新公告:前三季度净利同比预增101%-145%
证券之星 · 10-13
圣诺生物最新公告:前三季度净利同比预增101%-145%
每周股票复盘:圣诺生物(688117)股东减持39.0万股致持股比降至7.00%
证券之星 · 09-21
每周股票复盘:圣诺生物(688117)股东减持39.0万股致持股比降至7.00%
9月17日圣诺生物发布公告,股东减持39万股
证券之星 · 09-17
9月17日圣诺生物发布公告,股东减持39万股
9月1日圣诺生物涨5.33%,华商智能生活灵活配置混合A基金重仓该股
证券之星 · 09-01
9月1日圣诺生物涨5.33%,华商智能生活灵活配置混合A基金重仓该股
每周股票复盘:圣诺生物(688117)上半年营收增69.69%,海外销售团队持续扩展
证券之星 · 08-24
每周股票复盘:圣诺生物(688117)上半年营收增69.69%,海外销售团队持续扩展
8月22日增减持汇总:长江电力增持 圣诺生物等8股减持(表)
新浪证券 · 08-22
8月22日增减持汇总:长江电力增持 圣诺生物等8股减持(表)
圣诺生物最新公告:股东川发投资、卢昌亮、王晓莉拟减持不超过3.43%
证券之星 · 08-22
圣诺生物最新公告:股东川发投资、卢昌亮、王晓莉拟减持不超过3.43%
加载更多
公司概况
公司名称:
成都圣诺生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2021-06-03
主营业务:
成都圣诺生物科技股份有限公司的主营业务是多肽原料药和制剂产品的研发、生产与销售,同时提供多肽创新药药学研究服务、多肽类产品定制生产服务以及左西孟旦制剂代加工和左西孟旦原料药生产与出口。公司的主要产品是多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。
发行价格:
17.90
{"stockData":{"symbol":"688117","market":"SH","secType":"STK","nameCN":"圣诺生物","latestPrice":40.5,"timestamp":1764918001000,"preClose":40.59,"halted":0,"volume":2854792,"delay":0,"changeRate":-0.0022,"floatShares":157000000,"shares":157000000,"eps":0.7631,"marketStatus":"已收盘","change":-0.09,"latestTime":"12-05 15:00:01","open":40.1,"high":40.77,"low":39.9,"amount":115000000,"amplitude":0.0214,"askPrice":40.5,"askSize":58,"bidPrice":40.48,"bidSize":13,"shortable":0,"etf":0,"ttmEps":0.7631,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":40.59,"symbolType":"stock_kcb","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":44.65,"lowLimit":36.53,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":157385978,"isCdr":false,"pbRate":6.18,"roa":"--","peRate":53.072992,"roe":"12.94%","epsLYR":0.45,"committee":0.602428,"marketValue":6374000000,"turnoverRate":0.0181,"status":1,"afterMarket":{"amount":0,"volume":0,"close":40.5,"buyVolume":0,"sellVolume":421,"time":1764920037768,"indexStatus":"已收盘 12-05 15:30:00","preClose":40.59},"floatMarketCap":6374000000},"requestUrl":"/m/hq/s/688117","defaultTab":"news","newsList":[{"id":"2588012048","title":"圣诺生物(688117.SH):五肽-18通过化妆品新原料备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2588012048","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588012048?lang=zh_cn&edition=full","pubTime":"2025-12-03 18:07","pubTimestamp":1764756424,"startTime":"0","endTime":"0","summary":"智通财经APP讯,圣诺生物(688117.SH)发布公告,公司全资子公司成都凯捷多肽科技有限公司的化妆品原料五肽-18于近日通过国家药品监督管理局化妆品新原料备案。公司本次备案成功的化妆品新原料五肽-18是一种可用于各类化妆品的皮肤保护剂,在化妆品成品中的安全使用量可达1.86%。通过协助改善皮肤刺激状态等,从而达到皮肤保护的作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"圣诺生物(688117.SH):五肽-18通过化妆品新原料备案","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2588803181","title":"圣诺生物(688117)披露拟换届董事会人选,12月02日股价下跌0.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588803181","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588803181?lang=zh_cn&edition=full","pubTime":"2025-12-02 17:54","pubTimestamp":1764669284,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘,圣诺生物报收于39.2元,较前一交易日下跌0.99%,最新总市值为61.7亿元。该股当日开盘39.22元,最高39.96元,最低38.68元,成交额达9955.13万元,换手率为1.63%。本次会议主要审议关于公司董事会换届选举第五届董事会非独立董事和独立董事的议案,共提名6名非独立董事和3名独立董事候选人。股权登记日为2025年12月10日,股东可于2025年12月12日前办理参会登记。公告显示,会议不涉及关联股东回避表决及优先股股东参与表决事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200027285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2587796707","title":"圣诺生物最新公告:董事、高管拟合计减持不超0.024%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2587796707","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587796707?lang=zh_cn&edition=full","pubTime":"2025-11-30 16:10","pubTimestamp":1764490247,"startTime":"0","endTime":"0","summary":"圣诺生物(688117.SH)公告称,公司副总经理马中刚计划减持不超过1.88万股,即不超过公司总股本的0.0120%;董事、副总经理、财务负责人伍利计划减持不超过1.88万股,即不超过公司总股本的0.0120%。减持方式为集中竞价或大宗交易,减持原因为个人资金需求,减持期间为2025年12月23日至2026年3月22日。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025113000002388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2586395862","title":"11月26日圣诺生物涨6.99%,华商智能生活灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586395862","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586395862?lang=zh_cn&edition=full","pubTime":"2025-11-26 15:33","pubTimestamp":1764142390,"startTime":"0","endTime":"0","summary":"证券之星消息,11月26日圣诺生物涨6.99%,收盘报42.1元,换手率6.57%,成交量10.33万手,成交额4.34亿元。重仓圣诺生物的公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共6家,其中持有数量最多的公募基金为华商基金的华商智能生活灵活配置混合A。华商智能生活灵活配置混合A目前规模为2.37亿元,最新净值1.754,较上一交易日上涨4.97%,近一年上涨43.77%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600017603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2585278105","title":"每周股票复盘:圣诺生物(688117)维培那肽原料药获上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2585278105","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585278105?lang=zh_cn&edition=full","pubTime":"2025-11-23 04:09","pubTimestamp":1763842152,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,圣诺生物报收于38.09元,较上周的38.77元下跌1.75%。本周,圣诺生物11月17日盘中最高价报39.36元。11月19日盘中最低价报36.27元。圣诺生物当前最新总市值59.95亿元,在化学制药板块市值排名87/151,在两市A股市值排名2791/5167。维培那肽为聚乙二醇化艾塞那肽,属于GLP-1受体激动剂,可用于治疗2型糖尿病和肥胖症。此次获批符合药品注册相关要求,生产工艺、质量标准和包装标签按所附执行。具体销售情况受政策和市场环境影响存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300001137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"1133054293","title":"圣诺生物宣布其子公司获得中国医疗监管机构批准,维塞佩肽正式进入市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1133054293","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133054293?lang=zh_cn&edition=full","pubTime":"2025-11-19 16:08","pubTimestamp":1763539689,"startTime":"0","endTime":"0","summary":"圣诺生物宣布其子公司获得中国医疗监管机构批准,维塞佩肽正式进入市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2584291547","title":"圣诺生物(688117.SH):维培那肽原料药获得上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2584291547","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584291547?lang=zh_cn&edition=full","pubTime":"2025-11-19 16:02","pubTimestamp":1763539360,"startTime":"0","endTime":"0","summary":"智通财经APP讯,圣诺生物(688117.SH)发布公告,公司全资子公司成都圣诺生物制药有限公司于近日收到国家药品监督管理局(以下简称“国家药监局”)签发的关于维培那肽原料药的《化学原料药上市申请批准通知书》。据悉,维培那肽,是一种聚乙二醇(PEG)化的艾塞那肽,可结合并激活体内GLP-1受体作为GLP-1受体激动剂,具有与天然人体GLP-1相似的生理作用,通过增强胰岛素的分泌,以葡萄糖依赖性的方式降低血糖水平,从而治疗2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"圣诺生物(688117.SH):维培那肽原料药获得上市申请批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2582287877","title":"圣诺生物(688117)披露2025年中期权益分派实施公告,11月10日股价上涨0.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582287877","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582287877?lang=zh_cn&edition=full","pubTime":"2025-11-10 22:35","pubTimestamp":1762785322,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘,圣诺生物报收于38.99元,较前一交易日上涨0.26%,最新总市值为61.36亿元。该股当日开盘38.78元,最高39.47元,最低38.68元,成交额达7739.67万元,换手率为1.26%。公司近日发布公告称,将实施2025年中期权益分派,每股派发现金红利0.03176元(含税),股权登记日为2025年11月14日,除权(息)日和现金红利发放日均为2025年11月17日。本次分配以公司总股本157,385,978股为基数,共派发现金红利4,998,578.66元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000034908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2580479868","title":"每周股票复盘:圣诺生物(688117)前三季净利增123.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580479868","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580479868?lang=zh_cn&edition=full","pubTime":"2025-11-02 04:13","pubTimestamp":1762027991,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,圣诺生物报收于41.41元,较上周的38.45元上涨7.7%。本周,圣诺生物10月31日盘中最高价报42.12元。本周关注点来自业绩披露要点:圣诺生物2025年前三季度归母净利润1.27亿元,同比上升123.03%。股本股东变化截至2025年9月30日,圣诺生物股东户数为1.01万户,较6月30日减少1061户,减幅9.53%。业绩披露要点圣诺生物2025年三季报显示,主营收入5.20亿元,同比上升53.96%;归母净利润1.27亿元,同比上升123.03%;扣非净利润1.26亿元,同比上升134.97%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2578369679","title":"圣诺生物(688117)9月30日股东户数1.01万户,较上期减少9.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578369679","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578369679?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:23","pubTimestamp":1761643413,"startTime":"0","endTime":"0","summary":"证券之星消息,近日圣诺生物披露,截至2025年9月30日公司股东户数为1.01万户,较6月30日减少1061.0户,减幅为9.53%。在化学制药行业个股中,圣诺生物股东户数低于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.38万户。从股价来看,2025年6月30日至2025年9月30日,圣诺生物区间涨幅为21.58%,在此期间股东户数减少1061.0户,减幅为9.53%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800031203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2578361230","title":"图解圣诺生物三季报:第三季度单季净利润同比增长8.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578361230","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578361230?lang=zh_cn&edition=full","pubTime":"2025-10-27 18:23","pubTimestamp":1761560613,"startTime":"0","endTime":"0","summary":"证券之星消息,圣诺生物2025年三季报显示,公司主营收入5.2亿元,同比上升53.96%;归母净利润1.27亿元,同比上升123.03%;扣非净利润1.26亿元,同比上升134.97%;其中2025年第三季度,公司单季度主营收入1.83亿元,同比上升31.43%;单季度归母净利润3805.35万元,同比上升8.23%;单季度扣非净利润3659.84万元,同比上升5.98%;负债率45.95%,投资收益105.57万元,财务费用1111.45万元,毛利率56.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700028282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117"],"gpt_icon":0},{"id":"2576339049","title":"每周股票复盘:圣诺生物(688117)前三季度净利预增100.53%至145.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576339049","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576339049?lang=zh_cn&edition=full","pubTime":"2025-10-19 03:22","pubTimestamp":1760815330,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘,圣诺生物报收于39.1元,较上周的41.34元下跌5.42%。本周,圣诺生物10月14日盘中最高价报41.8元。来自公司公告汇总:股东一致行动关系解除,赛诺投资仍持公司30.39%股份。业绩披露要点圣诺生物预计2025年1-9月归属净利润为1.14亿元至1.4亿元,扣非后净利润为1.13亿元至1.39亿元。公司公告汇总圣诺生物预计2025年前三季度归母净利润为11,419.66万元至13,957.36万元,同比增长100.53%至145.10%;扣非净利润为11,335.46万元至13,854.46万元,同比增长111.26%至158.21%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2575893932","title":"股市必读:圣诺生物(688117)预计2025年1-9月扣非后净利润盈利1.13亿元至1.39亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575893932","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575893932?lang=zh_cn&edition=full","pubTime":"2025-10-14 01:13","pubTimestamp":1760375593,"startTime":"0","endTime":"0","summary":"截至2025年10月13日收盘,圣诺生物报收于41.58元,上涨0.58%,换手率3.44%,成交量5.42万手,成交额2.2亿元。业绩披露要点业绩预告圣诺生物发布业绩预告,预计2025年1-9月扣非后净利润盈利1.13亿元至1.39亿元;预计同期归属净利润盈利1.14亿元至1.4亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400027004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117"],"gpt_icon":0},{"id":"2575743474","title":"圣诺生物最新公告:前三季度净利同比预增101%-145%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575743474","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575743474?lang=zh_cn&edition=full","pubTime":"2025-10-13 17:40","pubTimestamp":1760348457,"startTime":"0","endTime":"0","summary":"圣诺生物(688117.SH)发布2025年前三季度业绩预告,预计归属于母公司所有者的净利润为1.14亿元至1.40亿元,同比增加100.53%至145.10%。报告期内,公司主营业务稳定发展,投建产能陆续落地,多肽原料药业务订单需求持续增长,带动整体业绩稳步提升,市场竞争力与持续盈利能力增强。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300020511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2569245354","title":"每周股票复盘:圣诺生物(688117)股东减持39.0万股致持股比降至7.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569245354","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569245354?lang=zh_cn&edition=full","pubTime":"2025-09-21 02:50","pubTimestamp":1758394222,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘,圣诺生物报收于38.52元,较上周的40.77元下跌5.52%。本周,圣诺生物9月15日盘中最高价报41.38元。本周关注点股本股东变化:股东川发投资减持39.0万股,持股比例由7.25%降至7.00%。公司公告汇总成都圣诺生物科技股份有限公司于2025年9月18日发布公告,持股5%以上股东川发投资在2025年9月15日至9月17日期间通过集中竞价方式减持公司股份390,026股,占公司总股本的0.25%。该股东无一致行动人,本次变动无需披露权益变动报告书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100000568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2568498396","title":"9月17日圣诺生物发布公告,股东减持39万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2568498396","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568498396?lang=zh_cn&edition=full","pubTime":"2025-09-17 19:01","pubTimestamp":1758106887,"startTime":"0","endTime":"0","summary":"证券之星消息,9月17日圣诺生物发布公告《圣诺生物:关于持股5%以上股东权益变动触及1%刻度的提示性公告》,其股东四川发展证券投资基金管理有限公司-四川资本市场纾困发展证券投资基金合伙企业(有限合伙)于2025年9月15日至2025年9月17日间合计减持39.0万股,占公司目前总股本的0.2478%,变动期间该股股价下跌3.19%,截止9月17日收盘报39.47元。股东增减持详情见下表:根据圣诺生物2025年中报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700034488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2564897440","title":"9月1日圣诺生物涨5.33%,华商智能生活灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2564897440","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564897440?lang=zh_cn&edition=full","pubTime":"2025-09-01 16:22","pubTimestamp":1756714961,"startTime":"0","endTime":"0","summary":"证券之星消息,9月1日圣诺生物涨5.33%,收盘报44.5元,换手率6.23%,成交量9.81万手,成交额4.28亿元。根据2025基金半年报公募基金重仓股数据,重仓该股的公募基金共4家,其中持有数量最多的公募基金为华商基金的华商智能生活灵活配置混合A。华商智能生活灵活配置混合A目前规模为1.91亿元,最新净值1.747,较上一交易日上涨0.46%,近一年上涨62.81%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100021122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2561230492","title":"每周股票复盘:圣诺生物(688117)上半年营收增69.69%,海外销售团队持续扩展","url":"https://stock-news.laohu8.com/highlight/detail?id=2561230492","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561230492?lang=zh_cn&edition=full","pubTime":"2025-08-24 03:30","pubTimestamp":1755977429,"startTime":"0","endTime":"0","summary":"截至2025年8月22日收盘,圣诺生物报收于43.31元,较上周的43.33元下跌0.05%。本周,圣诺生物8月20日盘中最高价报47.97元。其中,原料药收入18888.60万元,同比增长232.38%,主要为司美格鲁肽和替尔泊肽出口销售增加,带动公司业绩增长。公司公告汇总截至公告披露日,川发投资持有公司股份11,407,021股,占公司总股本的7.2478%,均为无限售流通股。王晓莉女士持有公司股份2,298,786股,占公司总股本的1.4606%。王晓莉女士拟减持不超过574,696股,即不超过公司总股本的0.3652%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082400000627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117"],"gpt_icon":0},{"id":"2561864403","title":"8月22日增减持汇总:长江电力增持 圣诺生物等8股减持(表)","url":"https://stock-news.laohu8.com/highlight/detail?id=2561864403","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561864403?lang=zh_cn&edition=full","pubTime":"2025-08-22 22:36","pubTimestamp":1755873360,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 据统计,8月22日,盘后长江电力披露增持情况。包括盾安环境、佳缘科技、顺威股份(维权)、新强联、德才股份、安乃达、圣诺生物、万业企业在内的8家A股上市公司披露减持情况。\n\n \n\n\n\n\n\n\n\n新浪声明:此消息系转载自新浪合作媒体,新浪网登载此文出于传递更多信息之目的,并不意味着赞同其观点或证实其描述。文章内容仅供参考,不构成投资建议。投资者据此操作,风险自担。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-08-22/doc-infmwrzy5326047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0183","LU1997245177.USD","LU2399975544.HKD","LU0821914370.USD","LU0192582467.USD","BK0179","BK0028","BK0239","LU0898667661.SGD","688117","BK0196","LU1634259391.SGD","LU1961090484.USD","LU1585245621.USD","LU2213484517.USD","LU1997245094.SGD","LU1969619763.USD","LU1580142542.USD","LU1720050803.USD","SG9999001846.SGD","LU0205439572.USD","LU1430594728.SGD","BK0175","LU0320764599.SGD","BK0006","LU1688375341.USD","600900","LU0052750758.USD","LU0039217434.USD","LU0516423091.SGD","LU0823426480.USD","LU0516423174.USD","LU1522347837.USD","LU2289578879.USD","BK0188","LU0516422952.EUR","LU1064130708.USD","BK0271","LU1255011170.USD","LU1997244956.HKD","LU1634259557.SGD","LU1497734951.SGD","LU1119993845.HKD","LU2148510915.USD","LU0516422440.USD","LU0188438112.USD","LU1497733631.SGD","LU1328615791.USD","LU1655091616.SGD","LU0831103253.SGD"],"gpt_icon":0},{"id":"2561427413","title":"圣诺生物最新公告:股东川发投资、卢昌亮、王晓莉拟减持不超过3.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561427413","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561427413?lang=zh_cn&edition=full","pubTime":"2025-08-22 17:21","pubTimestamp":1755854506,"startTime":"0","endTime":"0","summary":"圣诺生物(688117.SH)公告称,股东川发投资拟减持不超过4,721,578股,占公司总股本的3%;副总经理卢昌亮拟减持不超过96,579股,占公司总股本的0.0614%;董事、副总经理王晓莉拟减持不超过574,696股,占公司总股本的0.3652%。减持期间为2025年9月15日至12月14日。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082200031543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765009822157,"stockEarnings":[{"period":"1week","weight":-0.0122},{"period":"1month","weight":0.0366},{"period":"3month","weight":-0.0133},{"period":"6month","weight":0.3783},{"period":"1year","weight":0.9636},{"period":"ytd","weight":1.2169}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都圣诺生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10072人(较上一季度减少9.53%)","perCapita":"15626股","listingDate":"2021-06-03","address":"四川省成都市大邑县大安路98号","registeredCapital":"15738万元","survey":" 成都圣诺生物科技股份有限公司的主营业务是多肽原料药和制剂产品的研发、生产与销售,同时提供多肽创新药药学研究服务、多肽类产品定制生产服务以及左西孟旦制剂代加工和左西孟旦原料药生产与出口。公司的主要产品是多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","listedPrice":17.9},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"圣诺生物(688117)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供圣诺生物(688117)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"圣诺生物,688117,圣诺生物股票,圣诺生物股票老虎,圣诺生物股票老虎国际,圣诺生物行情,圣诺生物股票行情,圣诺生物股价,圣诺生物股市,圣诺生物股票价格,圣诺生物股票交易,圣诺生物股票购买,圣诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"圣诺生物(688117)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供圣诺生物(688117)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}